Reference Hellmich B, Sanchez-Alamo B, Schirmer JH, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 Update.

The ANCA test can also show if the treatment you take for vasculitis is working. And your doctor can use it to predict whether your symptoms might come back after treatment, which is called a relapse.

A total of 144 patients with ENT manifestations (avacopan, n=75; prednisone taper, n=69) and 142 with lung manifestations (avacopan, n=71; prednisone taper, n=71) were enrolled in the ADVOCATE ...

Managing ANCA Vasculitis: Updated British Guideline ‘Transcends’ Specialties Sara Freeman May 13, 2025 0 ...

Bacterial DNA Motifs Trigger ANCA Production in ANCA-Associated Vasculitis in Remission Tadema H, Abdulahad WH, Lepse N, Stegeman CA, Kallenberg CG, Heeringa P Rheumatology (Oxford). 2011;50:689-696 ...

Avacopan was better than prednisone in reducing respiratory as well as ear, nose and throat (ENT) involvement and enabled reduced glucocorticoid use in ANCA-associated vasculitis patients ...

Source: Hajj-Ali R. Abstract 2492. Presented at: ACR Convergence 2023; Nov. 10-15, 2023; San Diego.

Wegener's granulomatosis is characterized by granulomatous vasculitis of the upper and lower respiratory tracts and glomerulonephritis. In addition to this classic triad, vasculitis or granuloma, or ...

The FDA approves ChemoCentryx's (CCXI) lead drug Tavneos to treat ANCA-associated vasculitis. It is the company's first drug to get FDA approval. Resultantly, the stock gains in pre-market trading.

Higher SNOT-22 scores were reported “months to years” prior to ANCA-associated vasculitis relapse. The questionnaire score could be useful in selective escalation or de-escalation of therapy.

“ANCA-associated vasculitis is officially designated an intractable disease in Japan, indicating a rare disease without any effective treatment but for which long-term treatment is required. There is ...